A 5-HT1A ligand with both antidepressant and anxiolytic properties
Cott, J.M.; Kurtz, N.M.; Robinson, D.S.; Lancaster, S.P.; Copp, J.E.
Psychopharmacology Bulletin 24(1): 164-167
1988
ISSN/ISBN: 0048-5764 PMID: 2898794 Document Number: 319436
Document emailed within 1 workday
Related Documents
Przegaliński, E.; Tatarczyńska, E.; Chojnacka-Wójcik, E. 1998: Anxiolytic- and antidepressant-like effects of an antagonist at glycineB receptors Polish Journal of Pharmacology 50(4-5): 349-354Koek, W.; Patoiseau, J.F.; Assié, M.B.; Cosi, C.; Kleven, M.S.; Dupont-Passelaigue, E.; Carilla-Durand, E.; Palmier, C.; Valentin, J.P.; John, G.; Pauwels, P.J.; Tarayre, J.P.; Colpaert, F.C. 1998: F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential Journal of Pharmacology and Experimental Therapeutics 287(1): 266-283
Tatarczyńska, E.; Pałucha, A.; Szewczyk, B.; Chojnacka-Wójcik, E.; Wierońska, J.; Pilc, A. 2002: Anxiolytic- and antidepressant-like effects of group IIi metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats Polish Journal of Pharmacology 54(6): 707-710
Volchegorskiĭ, I.A.; Miroshnichenko, I.I.; Rassokhina, L.M.; Faĭzullin, R.M.; Malkin, M.P.; Priakhina, K.E.; Kalugina, A.V. 2014: Anxiolytic and antidepressant effects of 3-oxypiridine and succinic acid derivatives in the acute phase of alloxan-induced diabetes in rats Eksperimental'naia i Klinicheskaia Farmakologiia 77(4): 14-20
Herrmann, W.M.; Beach, R.C. 1978: Experimental and clinical findings indicating anxiolytic properties of gestagens Arzneimittel-Forschung 28(8): 1299
Smith, I.; Monk, T.G.; White, P.F.; Ding, Y. 1994: Propofol infusion during regional anesthesia: sedative, amnestic, and anxiolytic properties Anesthesia and Analgesia 79(2): 313-319
Danchev, N.; Yaneva, I.; Popov, P.; Staneva-Stoycheva, D. 1987: Behavioural and radioligand analysis of the effect of two new piperazine derivatives with anxiolytic properties Acta Physiologica et Pharmacologica Bulgarica 13(4): 37-42
Lipman, R.; Vanov, S.K.; Richards, D.J. 1977: A multiclinic double-blind trial of the anxiolytic properties of lorazepam in psychiatric outpatient practice Psychopharmacology Bulletin 13(2): 17-19
Hamon, M.; Fattaccini, C.M.; Adrien, J.; Gallissot, M.C.; Martin, P.; Gozlan, H. 1988: Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties Journal of Pharmacology and Experimental Therapeutics 246(2): 745-752
Chukniĭski, P.; Kavardzhikov, V.; Zlatanov, I. 1976: Ligand binding process and regulatory properties of proteins Biofizika 21(6): 1124-1125
Rutkowska, M.; Jachimczuk, O. 2004: Antidepressant--like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors Acta Poloniae Pharmaceutica 61(2): 165-167
Leysen, J.E.; Gommeren, W. 1982: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor Archives Internationales de Pharmacodynamie et de Therapie 260(2): 287-289
Brennan, F.J.; Cassidy, D.M. 1988: Effects of tetracyclic antidepressant drugs on the electrophysiological properties of canine cardiac Purkinje fibres Canadian Journal of Cardiology 4(6): 281-286
Lanier, B.; Raddatz, R.; Bakthavachalam, V.; Coupry, I.; Neumeyer, J.L.; Lanier, S.M. 1995: Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit Molecular Pharmacology 48(4): 703-710
Rinken, A. 1995: Subtype-specific changes in ligand binding properties after solubilization of muscarinic receptors from baculovirus-infected Sf9 insect cell membranes Journal of Pharmacology and Experimental Therapeutics 272(1): 8-14
McCombs, J.S.; Nichol, M.B.; Stimmel, G.L.; Sclar, D.A.; Beasley, C.M.; Gross, L.S. 1990: The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population Journal of Clinical Psychiatry 51 Suppl: 60-69; Discussion: 70-71
Wolfer, G.K.; Rippon, W.B. 1987: Protocols for use of ultrafiltration in determination of free ligand concentration and of complexity of ligand/protein interactions Clinical Chemistry 33(1): 115-117
Gryzunov, I.A.; Komarova, M.N. 2004: A study of ligand binding to protein using resonance energy transfer from the isoindole fluorescent label to ligand Biofizika 49(6): 979-986
Matsui, K.; Fine, A.; Zhu, B.; Marshak-Rothstein, A.; Ju, S.T. 1998: Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma Journal of Immunology 161(7): 3469-3473
Mantzouranis, E.C.; Stollar, B.D.; Borel, Y. 1980: The fine specificity of tolerance to simple haptens (nucleosides and DNP): induction of immunologic tolerance to one ligand may prime the animal to an analogous ligand Journal of Immunology 124(5): 2474-2480